(858) 665-2278

KPV Peptide: Derived From the Alpha-MSH Sequence
RESEARCH USE ONLY - NOT FDA-APPROVED

KPV is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.

Status as of July 14, 2026

What is KPV and how is it derived from alpha-MSH?

KPV is the final three-amino-acid tail of alpha-MSH, studied in preclinical models as an anti-inflammatory fragment rather than a proven drug. The larger hormone's pigment-signaling core is left out, so the interest in this tripeptide sits almost entirely in cell-culture and animal data, not human trials.

Sequence: Lysine-Proline-Valine (K-P-V) Origin: C-terminal residues 11-13 of alpha-MSH Molecular weight: ~342 daltons Production: solid-phase peptide synthesis Evidence: preclinical only, not FDA-approved
The Bottom Line

KPV is a synthetic lysine-proline-valine tripeptide matching residues 11 to 13 of alpha-MSH, examined in preclinical studies as an anti-inflammatory agent and not approved as a drug in any jurisdiction.

What is the amino acid composition and structure of KPV?

The peptide reads lysine-proline-valine from the amino end to the carboxyl end, joined by two peptide bonds. Proline in the center gives the backbone a built-in kink, and the literature ties that rigidity to how the molecule presents itself to binding partners.

  • Lysine (K): basic residue with a primary-amine side chain, positively charged at physiological pH.
  • Proline (P): ring-forming side chain that loops to the backbone nitrogen, limiting rotation.
  • Valine (V): small hydrophobic residue with a branched side chain at the carboxyl end.
  • Terminal chemistry: free-acid and C-terminal amide forms both appear in the literature, so a batch's certificate of analysis is the record that confirms which.
Key Fact

KPV is a linear tripeptide of lysine, proline, and valine joined by two peptide bonds, with a central proline ring that reduces backbone flexibility.

What is alpha-MSH and what is its role in the body?

Alpha-MSH is a 13-residue neuropeptide cut from proopiomelanocortin, the same precursor that yields ACTH and beta-endorphin. Its reputation rests on pigmentation, but the published record gives it a second, separate job as an endogenous anti-inflammatory mediator, and that second role is what made a fragment of it worth studying alone.

  • Pigmentation: signals melanocytes through MC1R to produce the melanin that darkens skin and hair.
  • Appetite and energy: hypothalamic melanocortin signaling generally suppresses food intake.
  • Immune modulation: lowers pro-inflammatory cytokine production across skin, gut, and other tissue models.
  • Production sites: released from the pituitary, hypothalamus, and peripheral cells such as keratinocytes.
Worth Knowing

Alpha-MSH is a 13-amino-acid melanocortin neuropeptide cleaved from proopiomelanocortin that acts through the MC1R to MC5R receptors and serves both pigmentary and anti-inflammatory roles.

Why does the C-terminal tripeptide of alpha-MSH retain biological activity?

The surviving activity is credited to a mechanism that looks different from the receptor-driven pigment signaling of the full hormone. Laboratory work reports that KPV can act inside the cell rather than at a surface melanocortin receptor, though the exact targets and how far the finding carries beyond cell and animal models are still unsettled.

  • Intracellular action: reported to interfere with NF-kB signaling, lowering transcription of pro-inflammatory genes.
  • Cell entry: taken up in some intestinal models by peptide transporters such as PepT1.
  • Receptor independence: proposed to act without the surface melanocortin receptors the whole hormone needs.
  • Open question: the balance of receptor-dependent and receptor-independent routes remains unresolved in preclinical data.
Established Fact

The anti-inflammatory activity retained by KPV is attributed to receptor-independent, intracellular action, including reported interference with NF-kB signaling rather than melanocortin receptor binding.

How is KPV manufactured or synthesized for research use?

Research-grade KPV is built synthetically, not pulled from tissue, and the standard route for a tripeptide is solid-phase peptide synthesis. The chain is assembled one residue at a time on a resin, then cleaved, purified, and checked against its expected mass before it is packaged as a powder.

  1. Chain assembly: residues are added one at a time on an insoluble resin through repeated deprotection and coupling cycles.
  2. Cleavage: the finished peptide is released from the resin and its protecting groups removed.
  3. Purification: reversed-phase HPLC separates the target sequence from truncated and side-product peptides.
  4. Verification: mass spectrometry confirms the weight near 342 daltons and HPLC reports purity on a certificate of analysis.
  5. Storage: the material is distributed lyophilized and kept cold, reconstituted before use.
The Practical Move

KPV is produced by solid-phase peptide synthesis, purified by reversed-phase HPLC, and verified by mass spectrometry against its expected molecular weight near 342 daltons.

What is the regulatory and approval status of KPV?

KPV holds no marketing authorization from the FDA, the EMA, or any comparable regulator for any condition. In commerce it moves as a research chemical intended for laboratory work, which means therapeutic claims about it sit outside anything a regulator has reviewed, and the evidence stays dominated by preclinical studies.

  • Approval status: not authorized by the FDA, EMA, or other major regulators for any indication.
  • Commercial handling: sold as a research chemical or laboratory reagent, not a medicine.
  • Evidence base: dominated by cell-culture and animal studies, with limited registered human trial activity.
  • Safety data: human dosing, interactions, and long-term effects not established through controlled trials.
Regulatory Reality

KPV is not approved as a drug by the FDA, the EMA, or any major regulator, and is handled in commerce as a research chemical rather than a validated treatment.

What physicochemical properties characterize KPV?

As a bare tripeptide, KPV carries modest, well-defined chemistry: a molecular weight near 342 daltons and a basic, water-soluble character from its lysine side chain. Its practical weak point is stability, since short peptides like this are broken down quickly by peptidases, which is why research material is kept lyophilized and cold.

Molecular weight: ~342 daltons Free-acid formula: ~C16H31N5O4 Charge: basic, positive at physiological pH Solubility: water-soluble, counterion-dependent Stability: peptidase-sensitive, stored cold
Expert Note

KPV has a molecular weight near 342 daltons and a basic, water-soluble profile, but its bare tripeptide structure leaves it susceptible to rapid peptidase degradation.

Educational use only. This article describes what the published scientific and clinical literature reports about KPV. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.

This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.

Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.

Daniel Zengel
Written by Daniel Zengel
Medical Writer
Daniel Zengel is the principal owner of MD PEP and PRP Labs and a medical writer focused on neutral, primary‑source‑driven coverage of the peptide market. He draws on more than a decade in pharmaceutical and medical device roles, with a focus on regenerative medicine and platelet‑rich plasma (PRP) systems for US‑based clinics.

Need more help?

Have a question about this peptide? Send a note and we'll point you in the right direction.

Why you can trust this page

Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.